Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Human papillomavirus vaccine recombinant bivalent - Japan Vaccine/AstraZeneca

X
Drug Profile

Human papillomavirus vaccine recombinant bivalent - Japan Vaccine/AstraZeneca

Alternative Names: Cervarix; GSK-580299; HPV-16/18 vaccine - Japan Vaccine; Human papillomavirus (types 6, 18) L1 virus-like particle vaccine - Japan Vaccine; Human Papillomavirus 16/18 L1 AS04 virus-like particle cervical cancer vaccine - Japan Vaccine; Human papillomavirus bivalent (types 16, 18) recombinant vaccine - Japan Vaccine; MEDI 517; MEDI-517 HPV-16/18 VLP AS04 vaccine

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MedImmune
  • Developer GlaxoSmithKline; GSK; Japan Vaccine
  • Class Cancer vaccines; Papillomavirus vaccines; Synthetic vaccines; Virus-like particle vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Anal cancer; Cervical cancer; Cervical intraepithelial neoplasia; Human papillomavirus infections
  • Preregistration Submission Withdrawal Head and neck cancer

Most Recent Events

  • 27 May 2022 9370550: updated KDM & HE
  • 27 May 2022 National Medical Products Administration approves human papillomavirus vaccine recombinant bivalent in girls aged between 9 to 14 years for the prevention of cervical cancer, cervical intraepithelial neoplasia and adenocarcinoma in China
  • 22 Oct 2021 Regulatory submission withdrawn for Head and neck cancer (In adolescents, In children, Prevention) in European Union (IM)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top